Literature DB >> 11418602

Growth hormone receptor ubiquitination, endocytosis, and degradation are independent of signal transduction via Janus kinase 2.

C M Alves dos Santos1, T ten Broeke, G J Strous.   

Abstract

The ubiquitin-proteasome system is required in growth hormone receptor (GHR) endocytosis. For cytokine receptors, which lack intrinsic tyrosine kinase activity, signal transduction is initiated by the activation of a member of the Janus kinase (JAK) family. Previously, we have shown that GHR and JAK2 tyrosine (de) phosphorylation are regulated via the ubiquitin system. In this study, we examined the role of JAK2-mediated signal transduction in GHR internalization and down-regulation. Mutation of the attachment site for JAK2, box-1, in the GHR cytoplasmic tail resulted in the complete absence of GHR and JAK2 phosphorylation. This modification did not alter the rate and extent of receptor-bound growth hormone internalization as compared with a functional GHR, nor did it change its turnover and transport to the plasma membrane. In addition, the receptor was still normally ubiquitinated and remained dependent on both an intact ubiquitin system and proteasomal action for its internalization. Thus, GHR ubiquitination, endocytosis, and degradation occur independently of GHR signal transduction via JAK2. We conclude that whereas endocytosis and degradation require the ubiquitin system, they are independent of GHR signal transduction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418602     DOI: 10.1074/jbc.M103583200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  Clathrin-dependent endocytosis.

Authors:  Seyed Ali Mousavi; Lene Malerød; Trond Berg; Rune Kjeken
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

2.  Ubiquitination regulates the internalization, endolysosomal sorting, and signaling of the erythropoietin receptor.

Authors:  Gamze Betul Bulut; Rita Sulahian; Yue Ma; Nai-wen Chi; Lily Jun-shen Huang
Journal:  J Biol Chem       Date:  2010-12-23       Impact factor: 5.157

3.  Growth hormone-induced JAK2 signaling and GH receptor down-regulation: role of GH receptor intracellular domain tyrosine residues.

Authors:  Luqin Deng; Jing Jiang; Stuart J Frank
Journal:  Endocrinology       Date:  2012-03-13       Impact factor: 4.736

4.  SRC family kinases accelerate prolactin receptor internalization, modulating trafficking and signaling in breast cancer cells.

Authors:  Timothy M Piazza; Juu-Chin Lu; Kristopher C Carver; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2008-12-04

Review 5.  Modulation of growth hormone receptor abundance and function: roles for the ubiquitin-proteasome system.

Authors:  Stuart J Frank; Serge Y Fuchs
Journal:  Biochim Biophys Acta       Date:  2008-06-09

6.  Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor.

Authors:  Mahban I Irandoust; Lambertus H J Aarts; Onno Roovers; Judith Gits; Stefan J Erkeland; Ivo P Touw
Journal:  EMBO J       Date:  2007-03-15       Impact factor: 11.598

7.  TYK2 activity promotes ligand-induced IFNAR1 proteolysis.

Authors:  Zrinka Marijanovic; Josiane Ragimbeau; K G Suresh Kumar; Serge Y Fuchs; Sandra Pellegrini
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

8.  Expression of a glycosylphosphatidylinositol-anchored ligand, growth hormone, blocks receptor signalling.

Authors:  François Guesdon; Yahia Kaabi; Aiden H Riley; Ian R Wilkinson; Colin Gray; David C James; Peter J Artymiuk; Jon R Sayers; Richard J Ross
Journal:  Biosci Rep       Date:  2012-12       Impact factor: 3.840

9.  Jak2 is a negative regulator of ubiquitin-dependent endocytosis of the growth hormone receptor.

Authors:  Joyce Putters; Ana C da Silva Almeida; Peter van Kerkhof; Agnes G S H van Rossum; Ana Gracanin; Ger J Strous
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

Review 10.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.